Compare MOVE & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOVE | PTHL |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.8M |
| IPO Year | 2021 | 2024 |
| Metric | MOVE | PTHL |
|---|---|---|
| Price | $8.57 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 139.2K | 99.1K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | $448,196.00 |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $0.47 |
| 52 Week High | $69.68 | $32.00 |
| Indicator | MOVE | PTHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 34.32 |
| Support Level | $7.22 | $0.50 |
| Resistance Level | $9.72 | $0.63 |
| Average True Range (ATR) | 1.08 | 0.04 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 29.48 | 15.10 |
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.